5 Best Mid-Cap Healthcare Stocks To Buy Now

3. Lantheus Holdings, Inc. (NASDAQ:LNTH)

Number of Hedge Fund Holders: 44

Lantheus Holdings, Inc. (NASDAQ:LNTH) operates globally and is involved in the development, production, and sale of diagnostic and therapeutic products that help doctors diagnose and treat a range of conditions including heart disease, cancer, and other illnesses. On April 24, Lantheus Holdings, Inc. (NASDAQ:LNTH) and POINT Biopharma Global Inc. (NASDAQ:PNT) disclosed that they have been given Fast Track designation by the US FDA for their candidate Lu-PNT2002, which is intended for the treatment of metastatic castration resistant prostate cancer. The Fast Track designation enables an accelerated review process, potentially leading to a quicker path to market for the asset.

On April 12, Truist raised the firm’s price target on Lantheus Holdings, Inc. (NASDAQ:LNTH) to $115 from $94 and kept a Buy rating on the shares. Truist’s model has been updated based on additional research and feedback from industry experts, which indicates that Lantheus Holdings, Inc. (NASDAQ:LNTH)’s previous assumptions regarding the anticipated decline in Pylarify’s average selling price were too conservative. As a result, the updated model predicts less pricing pressure on Pylarify and a more moderate decline in market share over the coming years compared to Truist’s previous projection.

According to Insider Monkey’s fourth quarter database, 44 hedge funds were bullish on Lantheus Holdings, Inc. (NASDAQ:LNTH), compared to 35 funds in the prior quarter. Ken Griffin’s Citadel Investment Group is the biggest stakeholder of the company, with 770,478 shares worth $39.2 million. 

Carillon Eagle Small Cap Growth Fund made the following comment about Lantheus Holdings, Inc. (NASDAQ:LNTH) in its Q4 2022 investor letter:

“Lantheus Holdings, Inc. (NASDAQ:LNTH) provides imaging diagnostics, targeted therapeutics, and artificial intelligence solutions used to fight serious medical conditions. Despite another strong quarterly update, the stock came under pressure due in part to investor concerns regarding a possible deceleration of revenue growth in the company’s leading product, Pylarify, as the company seems to have penetrated most of the early adopters of this imaging agent for prostate cancer. Later in the quarter, the company announced a strategic collaboration and exclusive licensing agreement for two late-stage therapeutic products used for the treatment of metastatic prostate cancer and neuroendocrine tumors. We believe approval of these products should help offset any significant declines in revenue growth of Pylarify.”